Mercer Global Advisors Inc. ADV Increases Stake in Koninklijke Philips (NYSE:PHG)

Mercer Global Advisors Inc. ADV increased its stake in Koninklijke Philips (NYSE:PHG) by 5.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,620 shares of the technology company’s stock after buying an additional 5,289 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Koninklijke Philips were worth $2,410,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mondrian Investment Partners LTD boosted its position in shares of Koninklijke Philips by 45.1% during the first quarter. Mondrian Investment Partners LTD now owns 9,553,058 shares of the technology company’s stock valued at $191,061,000 after purchasing an additional 2,971,008 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Koninklijke Philips by 27.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 4,036,336 shares of the technology company’s stock valued at $101,718,000 after buying an additional 864,951 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Koninklijke Philips by 36.4% during the 1st quarter. Russell Investments Group Ltd. now owns 1,410,067 shares of the technology company’s stock valued at $28,201,000 after buying an additional 376,244 shares in the last quarter. Natixis Advisors LLC increased its stake in shares of Koninklijke Philips by 5.2% in the 2nd quarter. Natixis Advisors LLC now owns 930,085 shares of the technology company’s stock worth $23,438,000 after acquiring an additional 46,268 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Koninklijke Philips by 16.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 917,560 shares of the technology company’s stock valued at $21,407,000 after acquiring an additional 129,830 shares during the period. 13.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Monday, July 15th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Koninklijke Philips currently has a consensus rating of “Hold”.

Koninklijke Philips Trading Down 1.4 %

NYSE PHG opened at $30.15 on Tuesday. The stock’s fifty day moving average price is $28.97 and its 200-day moving average price is $25.84. The company has a current ratio of 1.16, a quick ratio of 0.74 and a debt-to-equity ratio of 0.60. The stock has a market cap of $28.33 billion, a P/E ratio of -31.40, a P/E/G ratio of 1.06 and a beta of 0.73. Koninklijke Philips has a 12 month low of $17.75 and a 12 month high of $31.50.

Koninklijke Philips (NYSE:PHG) last issued its earnings results on Monday, July 29th. The technology company reported $0.32 earnings per share (EPS) for the quarter. Koninklijke Philips had a negative net margin of 2.35% and a positive return on equity of 10.15%. The business had revenue of $4.80 billion during the quarter. As a group, equities analysts forecast that Koninklijke Philips will post 1.51 EPS for the current fiscal year.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.